Explorer les evidences

Palier Gold : evidences validées mécaniquement, avec leur source primaire.

1 197 evidences · page 4 / 48

150 per_1000_person-yearsIn Mali, malaria incidence rose from 150 per 1000 person-years in 2021 to 172 per 1000 person-years in 2022.

Malipaludismeobservé 2021HAL · Unilimdocument de 111 observations

96,1 %Of 4333 delivering women, 4164 (96.1%) were offered sickle cell disease newborn screening (SCD NBS).

Malidrépanocytoseobservé 21 April to 17 August 2021HAL · Unilimdocument de 103 observations

50 %Sickle cell disease is associated with a high mortality of 50%–80% before 5 years of age without care management.

MalidrépanocytoseHAL · Unilimdocument de 103 observations

31,9 %Recognition of the SARS-CoV-2 proteins by sera from COVID-19 patients was 31.9% for RBM.

MaliCOVID-19HAL · Unilimdocument de 67 observations

20 585 casesSince the beginning of this outbreak (September 2023), a cumulative of 20,585 cases (2,755 confirmed; 17,830 suspected) and 75 deaths (CFR: 0.36%) of dengue fever have been reported from all 11 regions in Mali.

Malidengueobservé September 2023Africa CDCdocument de 6 observations

92 %Western blot serology was positive in 11 out of 12 cases, representing 92%.

Malicutaneous leishmaniasisobservé 2010publié 2012Bulletin de la Societe de pathologie exotique (1990)europe_pmcdocument de 4 observations

96,77 %Plasmodium falciparum était plus fréquent chez les individus symptomatiques (96,77 % vs. 93,24 %, p = 0,014).

MalipaludismeHAL · Unilimdocument de 214 observations

12,2 %Among children with sickle cell trait in Mali, the prevalence of severe versus uncomplicated malaria in children with the G6PD (A−) polymorphism was 12.2%.

MaliG6PD (A−) polymorphism · paludisme · trait drépanocytairepublié 2011American Journal of HematologyOpenAlexdocument de 9 observationsDOI 10.1002/ajh.22093

0,27 risk_ratioIn the study-level meta-analysis, treatment was associated with a reduction in Plasmodium falciparum prevalence with a risk ratio of 0.27.

Malipaludismepublié 2020The Lancet. Global healtheurope_pmcdocument de 6 observationsDOI 10.1016/s2214-109x(20)30325-9

5,61 timesPersons with diagnosed diabetes used 5.61 times more medications than matched comparison subjects without diabetes in Cameroon, Mali, Tanzania and South Africa during 2008–2009.

Afrique du Sud · Cameroun · Mali · Tanzaniediabète (non précisé)observé 2008–2009publié 2014PloS oneeurope_pmcdocument de 3 observations

13 msChez les patients porteurs de l'haplotype G/G du variant rs1805121, la médiane de la variation de l'intervalle QTc (ΔQTc) après traitement par DHA-PQ était de 13 ms (IC à 95 % : 4–23 ms).

MalipaludismeHAL · Unilimdocument de 62 observations

15,4 %Pretreatment HIV drug resistance (PDR) frequency was 15.4% in Mali.

MaliVIH/sidapublié 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument de 9 observationsDOI 10.1093/jac/dky443

1 122 episodesNonmalarial febrile illnesses occurred in 1122 episodes in the azithromycin group and 1424 episodes in the placebo group.

Burkina Faso · Malinonmalarial febrile illnessespublié 2019The New England journal of medicineeurope_pmcdocument de 4 observations

0,82 %Dans le groupe de dépistage passif, la prévalence des gamétocytes de Plasmodium falciparum était de 0,82 % chez les adolescents âgés de 10 à 14 ans.

MalipaludismeHAL · Unilimdocument de 214 observations

121 casesA total of 121 cases of leprosy and 219 controls aged 10–84 years old were included in the study from March 1999 to February 2000.

Malileprosyobservé March 1999 to February 2000publié 2002Medecine tropicale : revue du Corps de sante colonialeurope_pmcdocument de 7 observations

0,93 incidence_rate_ratioThe incidence rate ratio for other common diseases of childhood among G6PD c.202T homozygous girls or hemizygous boys was 0.93.

Maliother common diseases of childhoodpublié 2015The Lancet. Haematologyeurope_pmcdocument de 11 observationsDOI 10.1016/s2352-3026(15)00152-0

4 %In children who received RTS,S/AS01E vaccine in Burkina Faso and Mali, 4% showed a 10-fold increase in anti-CSP IgG antibody titres post-2020 as measured by Oxford MSD assay.

Burkina Faso · Malipaludismeobservé post-2020HAL · Unilimdocument de 105 observations

9,6 %False positivity against the three SARS-CoV-2 antigens was observed in 9.6% to 20.0% of cross-reactive samples from pre-COVID-19 volunteers.

MaliCOVID-19HAL · Unilimdocument de 67 observations

0,85 %The prevalence of HbSC among 3648 newborns in Mali was 0.85% (95% CI: 0.58–1.20).

MaliHbSCobservé April–August 2021HAL · Unilimdocument de 103 observations

278 per_1000_person-yearsThere were 278 events of uncomplicated clinical malaria per 1000 person-years at risk in the vaccine-alone group.

Malipaludismepublié 2021The New England journal of medicineeurope_pmcdocument de 10 observations

79 %The 2018 DHS reported a utilization rate of LLINs of 79% in children under 1 year in Mali.

Malipaludismeobservé 2018HAL · Unilimdocument de 111 observations

27,1 %Among 266 COVID-19 donor samples, 72 (27.1%) recognized all three antigens (S, RBD, and RBM).

MaliCOVID-19HAL · Unilimdocument de 67 observations

30,1 %In the COVID-19 sample group (N = 266), the prevalence of antibody responders against RBM was 30.1% among males.

MaliCOVID-19 · SARS-CoV-2 RBMHAL · Unilimdocument de 67 observations

1 998 casesFrom July 2021 to July 2022, 1998 severe cases were enrolled among children aged under 5 years attending IMCI consultations integrating pulse oximetry use at 16 research primary health centres in Burkina Faso, Guinea, Mali and Niger.

Burkina Faso · Guinée · Mali · Nigersevere illnessobservé July 2021 to July 2022HAL · Unilimdocument de 229 observations

85 %Au Mali, P. falciparum était responsable de 85 à 95 % des cas de paludisme rapportés selon la période de l’année.

MalipaludismeHAL · Unilimdocument de 214 observations

Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.